A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Hoffmann-La Roche · with Zealand Pharma · NCT07843472
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 2500
- US sites recruiting
- 3
- Study start
- September 30, 2026
- Record last updated
- October 7, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Being studied: Petrelintide; Placebo
Conditions: Obesity or Overweight; Cardiovascular Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants with BMI ≥ 27 kg/m² and established CVD
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion Criteria
- Known history of Type 1 diabetes mellitus
- Current or previous treatment with petrelintide or any other amylin analog
Recruiting US locations
Pinnacle Research Group
Anniston, AL 36207
Institute for Metabolic Research Los Angeles
Los Angeles, CA 90015
Progressive Medical Research
Port Orange, FL 32127
Study contacts (from the official record)
- Reference Study ID Number: CC46446 https://forpatients.roche.com/No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
- Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Similar studies in Alabama
All weight loss studies in Alabama →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Birmingham, AL + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Pelham, AL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Pelham, AL + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Birmingham, AL + 19 other US sites
- Eligibility basics
- Ages 18–75